Theremia is a precision medicine company specialized in neurology and psychiatry. Theremia develops explainable and causal AI models to help biotech and pharma companies de-risk and optimize drug development.

Founded in late 2023, Theremia stems from a simple observation: the current “one size fits all” model—one treatment, at one dose, for all patients—does not work in central nervous system (CNS) disorders. In these highly heterogeneous diseases, more than 60% of patients either do not respond to treatment or experience severe adverse effects, which largely explains high clinical failure rates.

To address this challenge, Theremia has developed a multi-scale AI integrating clinical, phenotypic, and pharmacological data to identify the right treatment for specific patient subpopulations based on their profiles and treatment responses. Leveraging causal inference methods, Theremia models treatment response to generate actionable insights compatible with regulatory decision-making.

Theremia’s platform is structured around three core use cases:
– Target Product Profile optimization: early identification of the most promising indications, endpoints, and patient subpopulations to maximize probability of success.
– Clinical trial design and execution: improved patient selection and construction of external control arms to de-risk Phase II/III trials, while reducing timelines and costs.
– Post-approval optimization and lifecycle extension: personalization of treatment parameters (e.g: dose optimization, PK/PD modeling) for potential repositioning or treatment optimization.

What makes Theremia’s technology unique is the combination of highly robust AI models with large-scale, high-quality data that are continuously enriched over time. Theremia leverages more than 1.5 million longitudinal patient records, combining clinical trial data and real-world evidence from Europe and the United States, together with a knowledge graph of over 9 million drugs and more than 20 million connections.

Theremia’s models and datasets are continuously enriched through collaborations with leading academic institutions and validated in partnership with top-tier hospitals, ensuring strong robustness, clinical relevance, and real-world applicability.